Alpine Immune Sciences (NASDAQ:ALPN) had its target price decreased by Piper Jaffray Companies to $8.00 in a research report released on Wednesday, The Fly reports. Piper Jaffray Companies currently has an overweight rating on the biotechnology company’s stock. Piper Jaffray Companies also issued estimates for Alpine Immune Sciences’ Q1 2021 earnings at ($0.81) EPS, Q2 2021 earnings at ($0.85) EPS and Q3 2021 earnings at ($0.85) EPS. The analysts noted that the move was a valuation call.
Several other analysts also recently weighed in on ALPN. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a sell rating to a hold rating in a research report on Monday, October 21st. ValuEngine upgraded shares of Alpine Immune Sciences from a sell rating to a hold rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Alpine Immune Sciences currently has an average rating of Buy and an average target price of $9.50.
Alpine Immune Sciences stock opened at $2.60 on Wednesday. Alpine Immune Sciences has a 12-month low of $2.25 and a 12-month high of $8.24. The company has a 50-day moving average price of $3.07 and a 200 day moving average price of $4.29. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.27. The stock has a market cap of $50.51 million, a P/E ratio of -0.99 and a beta of 1.82.
Large investors have recently modified their holdings of the company. Leonard Rickey Investment Advisors P.L.L.C. purchased a new stake in shares of Alpine Immune Sciences during the 2nd quarter worth approximately $42,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Alpine Immune Sciences during the 2nd quarter worth approximately $90,000. Renaissance Technologies LLC lifted its position in shares of Alpine Immune Sciences by 10.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after buying an additional 10,400 shares during the last quarter. Hikari Power Ltd lifted its position in shares of Alpine Immune Sciences by 52.9% during the 3rd quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock worth $735,000 after buying an additional 64,224 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Alpine Immune Sciences by 67.7% in the 2nd quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock valued at $853,000 after acquiring an additional 81,800 shares during the period. Institutional investors and hedge funds own 47.26% of the company’s stock.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Article: Why do companies engage in swaps?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.